STO · ENZY.ST
Enzymatica AB (publ)
SEK 2.13-SEK 0.02 (-0.93%)
Enzymatica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.35% below the high.
Loading market information…
STO · CLBIO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Corline Biomedical AB’s quoted price sits in the lower half of its reported 52-week range, 29.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Corline Biomedical AB’s next earnings report is currently expected on Nov 19, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Corline Biomedical AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 17, 2025 |
| -SEK 0.62 |
| SEK 2.01M-49.7% vs estimate |
| Q3 2024 | Nov 7, 2024 | -SEK 0.14 | SEK 1.77M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 2.13-SEK 0.02 (-0.93%)
Enzymatica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.35% below the high.
SEK 31.50+SEK 0.90 (+2.94%)
FluoGuide A/S’s quoted price sits in the lower half of its reported 52-week range, 34.1% below the high.
SEK 16.00-SEK 0.10 (-0.62%)
Bactiguard Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 25.93% below the high.
SEK 5.17-SEK 0.17 (-3.18%)
Mendus AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.1% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 0.78-SEK 0.00 (-0.64%)
Intervacc AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
SEK 2.74-SEK 0.11 (-3.69%)
Elicera Therapeutics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 60.86% below the high.
SEK 0.16+SEK 0.00 (+2.61%)
Xintela AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 67.32% below the high.
